Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Announces Digital Spatial Profiling Deals With Several CROs

NEW YORK (GenomeWeb) – NanoString Technologies said today that it has entered new commercial partnerships with five contract research organizations aimed at expanding access to its Digital Spatial Profiling (DSP) technology.

The agreements — with Covance, Cancer Genetics, Core Diagnostics, Propath UK, and another undisclosed company — will allow the CROS to market DSP services to their customers through a technology access program in advance of NanoString's expected commercial launch of the DSP instrument platform in 2019.

Digital Spatial Profiling is a technology NanoString developed to enable precise quantification of highly multiplexed targets while maintaining spatial information across a heterogeneous tissue sample.

Chad Brown, the company's senior vice president of sales and marketing, said in a statement that the agreements were borne out of increasing interest in DSP, especially among biopharmaceutical researchers. "By joining forces with this network of select CRO partners, we hope to increase customer awareness of DSP, accelerating its adoption following our full commercial launch," he said.